Alessandro Rocco

Use Of Famotidine And Related Compounds In The Treatment Of Movement Disorders

Application

#5496836 Mar 5, 1996

Filed

May 5, 1994

Inventor

Alessandro Di Rocco (New York, NY) · Susan Molinari (River Edge, NJ) · Ram Kaminski (Riverdale, NY)

Appl. No.

8/238704

Assignee

Mount Sinai School of Medicine of the City University of New York (New York, NY)

International Classification

A61K 31425

U.S. Classification

514370

Abstract

The present invention relates to methods of treating movement disorders which comprise administering famotidine or a related compound to a subject in need of such treatment, wherein the motor disorder is selected from the group consisting of olivo-ponto-cerebellar atrophy, multi-system atrophy, Shy-Drager syndrome, kernicterus, Leigh's disease, cerebellar ataxias, neonatal hypoxemia syndromes, carbon monoxide poisoning, progressive supranuclear palsy, tardive dystonias, oculogyral crises, manganese poisoning, Wilson's Disease, Huntington's Disease, striatonigral degeneration, ingestion by the subject of phenothiazines, butyrophenones or reserpine, Alzheimer's Disease, normal pressure hydrocephalus, obstructive hydrocephalus, physiologic tremor, benign familial tremor, cerebellar tremor, rubral tremor, toxic tremor, metabolic tremor, senile tremor, chorea, ballism, athetosis, dystonia, tics, tardive dyskinesia, paroxysmal choreoathetosis, tonic spasm, akathisia, muscle rigidity, postural instability, bradykinesia, difficulty in initiating movements, muscle cramps, dyskinesias, myoclonus, and Creutzfeldt-Jacob Disease, and wherein the subject does not exhibit bradyphrenia. In preferred embodiments of the invention, the movement disorder is associated with an abnormality in basal ganglia structure or function. In a particularly preferred embodiment of the invention, the movement disorder is a component of Parkinson's Disease.